Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, hereinafter called the “Company”) today announced that it decided the contents of the stock acquisition rights to be offered to the Directors (except for the Outside Directors) and Corporate Executives of the Company, resolved at the meeting of the Board of Directors held on June 19, 2013.
1. Name of stock acquisition rights to be offered:
Astellas Pharma Inc. Stock Acquisition Rights issued
in July 2013
2. Total number of stock acquisition rights to be offered:
707 units (100 shares per stock acquisition right)
3. Type and number of shares to be issued upon exercise of
stock acquisition rights:
Shares of common stock of the Company: 70,700 shares
4. The amount to be paid for stock acquisition rights
to be offered:
￥505,300 per stock acquisition right
(option value: ￥ 5,053 per share)
Besides above information, please refer to “Allotment of Stock Acquisition Rights (Stock Option Scheme as Stock-Linked Compensation Plan)” issued on June 19, 2013.